Criteria for evaluation of clinical efficacy of anticancer medicines

Criteria for evaluation of clinical efficacy of anticancer medicines

Criteria for evaluation of clinical efficacy make it possible to assess the risk-benefit ratio of anticancer medicines that patients receive, in particular, for the treatment of solid malignant tumors. A medicine’s efficacy is assessed using special criteria called the endpoints of clinical efficacy...

Full description

Bibliographic Details
Main Author:	A. V. Tikhomirova
Format:	Article
Language:	Russian
Published:	OOO “Vashe Tsifrovoe Izdatelstvo” 2019-03-01
Series:	Ведомости Научного центра экспертизы средств медицинского применения
Subjects:	endpoints clinical efficacy survival objective response subjective response quality of life anticancer medicines
Online Access:	https://www.vedomostincesmp.ru/jour/article/view/209

Similar Items

Planning a Clinical Development Programme for Medicines for Bronchial Asthma
by: E. S. Petrova, et al.
Published: (2021-03-01)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
by: Hideki Maeda, et al.
Published: (2021-06-01)

Optimising Clinical Trial Design in Older Cancer Patients
by: Shóna Whelehan, et al.
Published: (2018-06-01)

Recommendations on the Clinical Trial Programme for Diabetes Medicines
by: I. A. Proskurina, et al.
Published: (2021-07-01)

Editorial: Clinical Evaluation Criteria for Aging and Aging-Related Multimorbidity
by: Ilia Stambler, et al.
Published: (2021-09-01)

Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy
by: Andrea Callegaro, et al.
Published: (2019-03-01)

When do we need clinical endpoint adjudication in clinical trials?
by: Claes Held
Published: (2019-01-01)

Food and Drug Administration approvals in phase 3 Cancer clinical trials
by: Joseph Abi Jaoude, et al.
Published: (2021-06-01)

Surrogate endpoint evaluation using data from one large global randomized controlled trial
by: Milan Geybels, et al.
Published: (2021-05-01)

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?
by: Yvonne Schuller, et al.
Published: (2018-11-01)

Evaluation of the effectiveness of lipid-lowering agents
by: V. G. Shevko, et al.
Published: (2020-02-01)

Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy
by: Romain Daillère, et al.
Published: (2020-01-01)

CLINICAL SYMPTOMS AND MICROBIOLOGICAL OUTCOMES IN TUBERCULOSIS TREATMENT TRIALS
by: Bark, Charles
Published: (2011)

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
by: Andriy Krendyukov, et al.
Published: (2021-03-01)

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
by: Shixue Chen, et al.
Published: (2021-04-01)

Testing for Efficacy for Primary and Secondary Endpoints by Partitioning Decision Paths
by: Liu, Yi
Published: (2009)

Anticancer agents from medicinal plants
by: Mohammad Shoeb
Published: (2006-12-01)

l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells
by: Shiwei Niu, et al.
Published: (2018-01-01)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
by: Kümmel S, et al.
Published: (2018-11-01)

Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization
by: Lin Wang, et al.
Published: (2017-08-01)

Challenges in Conducting Studies in Chronic Graft-versus-Host Disease
by: Iskra Pusic, et al.
Published: (2019-03-01)

Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016
by: Gomon Yu.M., et al.
Published: (2017-08-01)

Anticancer activity of Nigerian medicinal plants: a review
by: Franklyn O. Ohiagu, et al.
Published: (2021-03-01)

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data
by: Yanjun Xu, et al.
Published: (2019-08-01)

Statistical considerations on implementing the MCP-Mod method for binary endpoints in clinical trials
by: Jingjing Chen, et al.
Published: (2020-09-01)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
by: Cicero G, et al.
Published: (2018-05-01)

Evaluating multiple endpoints in heart failure clinical trials
by: Yang, Yijun
Published: (2016)

Thapsigargin—From Traditional Medicine to Anticancer Drug
by: Agata Jaskulska, et al.
Published: (2021-12-01)

Current Approaches to Planning and Conducting Clinical Trials of Medicinal Products for the Treatment of Crohn's Disease
by: А. N. Bogdanov, et al.
Published: (2020-06-01)

Inconsistencies in assessment of pain endpoints in radiotherapy for painful tumors: Analysis of original articles in the Green and Red Journals
by: Tetsuo Saito, et al.
Published: (2020-09-01)

Complexity of design in early phase respiratory clinical trials; evaluating impact of primary endpoints and sponsor size
by: Nicolas Marco-Ariño, et al.
Published: (2021-06-01)

Towards a Clinical Efficacy Evaluation System Adapted for Personalized Medicine
by: Yuan B
Published: (2021-04-01)

Patient reported outcomes to support drug development decision making
by: Annabel Nixon, et al.
Published: (2015-06-01)

Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
by: Gita Bhat, et al.
Published: (2020-11-01)

TOWARDS THE CIVIC CODE OF REPUBLIC OF SERBIA – WHETHER THE ARTICLE 178 OF THE LAW OF CONTRACT FROM 1978 IS A GOOD SOLUTION?
by: Aleksandar Filipović K., et al.
Published: (2019-10-01)

Evaluation of Anticancer, Antioxidant, and Possible Anti-inflammatory Properties of Selected Medicinal Plants Used in Indian Traditional Medication
by: Rafik Shaikh, et al.
Published: (2014-10-01)

Leveraging hybrid biomarkers in clinical endpoint prediction
by: Maliazurina Saad, et al.
Published: (2020-10-01)

Gold Compounds and the Anticancer Immune Response
by: Ling Zhou, et al.
Published: (2021-09-01)

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology
by: Victoria J. Serpas, et al.
Published: (2018-12-01)

Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities
by: Beatrice Mainoli, et al.
Published: (2021-02-01)

Cannot write session to /tmp/vufind_sessions/sess_o6odkipf03k6uhut28e6ftp0su